Health Canada grants IVD approval to Devyser’s NGS-based chimerism test, the first of its kind in Canada
Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been...
One severe complication following solid organ transplantation is antibody- and/or cell-mediated rejections of the graft. Early detection of rejection may therefore be of paramount importance to improve graft survival following solid organ transplantation. The present study was conducted to determine the monitoring capability and clinical utility of the Devyser assay designed for the sensitive detection of dd-cfDNA (donor-derived cell-free DNA) in patients following kidney transplantation.
Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been...
Read More
Devyser today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its...
Read More
Devyser today announced the enrollment of the first patient in its Devyser Accept cfDNA clinical...
Read More
Devyser, a pioneer in advanced genetic testing solutions, is pleased to announce that its...
Read More